期刊
RHEUMATOLOGY
卷 60, 期 -, 页码 SI37-SI50出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keab250
关键词
COVID-19; autoimmune condition; mortality; hospitalization; open science; Observational Health Data Sciences and Informatics (OHDSI); Observational Medical Outcomes Partnership (OMOP)
类别
资金
- VA HSRD
- National Heart, Lung, and Blood Institute, (NHLBI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDLE), National Institutes of Health (NIH)
- US National Library of Medicine
- NIH
- National Library of Medicine
- US National Institutes of Health
- Department of Veterans Affairs
- IMI 2 Joint Undertaking (JU) [806968]
- European Union
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Bill & Melinda Gates Foundation [INV-016201]
- NIHR Oxford Biomedical Research Centre (BRC)
- US Department of Veterans Affairs
- Janssen Research Development
- IQVIA
- Bio Industrial Strategic Technology Development Program - Ministry of Trade, Industry & Energy (MOTIE, Korea) [20001234]
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI16C0992]
- Health Department from the Generalitat de Catalunya
- Direccio General de Recerca i Innovacioen Salut
- NIHR [SRF-2018-11-ST2-004]
- MRC-DTP [MR/K501256/1, MR/N013468/1]
- Fundacion Alfonso Martin Escudero (FAME)
- US National Library of Medicine [LM006910]
- Bill and Melinda Gates Foundation [INV-016201] Funding Source: Bill and Melinda Gates Foundation
- National Institutes of Health Research (NIHR) [SRF-2018-11-ST2-004] Funding Source: National Institutes of Health Research (NIHR)
In patients with prevalent autoimmune diseases, COVID-19 results in more complications and higher mortality rates compared to influenza, highlighting the severity of the disease.
Objective. Patients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza. Methods. A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30days of hospitalization. Results. We studied 133589 patients diagnosed and 48418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged >= 50years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%). Conclusion. Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据